So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Prime Minister Narendra Modi on Thursday released the genome sequencing data of 10,000 Indian nationals and said it will be a milestone in the field of biotechnology research. The Genome India ...

A year after a bearish market led to a year-over-year decline in the market capitalization (the product of the share price and the number of outstanding shares) of the top 25 public biotechnology ...

SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced initial ...

FARGO — Aldevron, a Fargo-based biotechnology firm, laid off 5% of its workforce this week, with a majority of the cuts occurring at its Fargo campuses. President Jennifer Meade confirmed to The ...

SAN FRANCISCO--(BUSINESS WIRE)--Biotechnology is set for significant transformation in 2025 with an incoming political administration, rapid scientific advancements, and the convergence of ...

Prospective health secretary Robert F. Kennedy Jr. invested in biotechnology and had multiple sources of income in 2022 and 2023, financial disclosures show. The documents, which STAT obtained ...

On Wednesday the U.S. Department of Commerce announced it would implement new export controls on certain biotechnology equipment, citing national security concerns relating to artificial ...

WASHINGTON, Jan 15 (Reuters) - The U.S. Commerce Department said Wednesday it is imposing new export controls on biotechnology equipment and related technology because of national security ...

1) The biotech industry is due for accelerating M&A activity due to extremely low valuations of many small-cap biotechs and the need of the big pharma boys to compensate for big upcoming losses of ...